KHO_BGBC008 (BerGenBio)

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in patients with previously treated, advanced adenocarcinoma of the lung.
Phase II
NCT03184571
Cancer
Lung
Rangaswamy Chintapatla, M.D.
BerGenBio ASA
Paul Alderson
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research